Effects of agmatine on cognitive functions during vascular dementia in biological aging through eNOS and BDNF expression

References

• Rincon F, Wright CB. Vascular cognitive impairment. Curr Opin Neurol. 2013;26:29–36. doi: 10.1097/WCO.0b013e32835c4f04
   PubMed Web of Science ®Google Scholar
• Ramos AR, Dib SI, Wright CB. Vascular dementia. Curr Transl Geriatr Exp Gerontol Rep. 2013;2(3):188–195. doi: 10.1007/s13670-013-0054-5
   PubMedGoogle Scholar
• Sudduth TL, Powell DK, Smith CD, et al. Induction of hyperhomocysteinemia models vascular dementia by induction of cerebral microhemorrhages and neuroinflammation. J Cereb Blood Flow Metab. 2013;33:708–715. doi: 10.1038/jcbfm.2013.1
   PubMed Web of Science ®Google Scholar
• Kennedy KM, Raz N. Aging White matter and cognition: differential effects of regional variations in diffusion properties on memory, executive functions, and speed. Neuropsychologia. 2009;47:916–927. doi: 10.1016/j.neuropsychologia.2009.01.001
   PubMed Web of Science ®Google Scholar
• Akinyemi RO, Mukaetova-Ladinska EB, Attems J, et al. Vascular risk factors and neurodegeneration in ageing related dementias: Alzheimer’s disease and vascular dementia. Curr Alzheimer Res. 2013;10(6):642–653. doi: 10.2174/15672050113109990037
   PubMed Web of Science ®Google Scholar
• de la Torre JC. Cardiovascular risk factors promote brain hypoperfusion leading to cognitive decline and dementia. Cardiovasc Psychiatry Neurol. 2012;2012:367516. doi: 10.1155/2012/367516
   PubMedGoogle Scholar
• Feldstein CA. Association between chronic blood pressure changes and development of Alzheimer’s disease. J Alzheimers Dis. 2012;32:753–763.
   PubMed Web of Science ®Google Scholar
• Shah NS, Vidal JS, Masaki K, et al. Midlife blood pressure, plasma beta-amyloid, and the risk for Alzheimer’s disease: Honolulu Asia Aging Study. Hypertension. 2012;59:780–789. doi: 10.1161/HYPERTENSIONAHA.111.178962
   PubMed Web of Science ®Google Scholar
• Miralbell J, Soriano JJ, Spulber G, et al. Structural brain changes and cognition in relation to markers of vascular dysfunction. Neurobiol Aging. 2012;33(5):1003.e9–17. doi: 10.1016/j.neurobiolaging.2011.09.020
   Web of Science ®Google Scholar
• Toth P, Tarantini S, Tucsek Z, et al. Resveratrol treatment rescues neurovascular coupling in aged mice: role of improved cerebromicrovascular endothelial function and downregulation of NADPH oxidase. Am J Physiol Heart Circ Physiol. 2014;306:H299–H308. doi: 10.1152/ajpheart.00744.2013
   PubMed Web of Science ®Google Scholar
• Utkan T, Yazir Y, Karson A, et al. Etanercept improves cognitive performance and increase eNOS and BDNF expression during experimental vascular dementia in streptozotocin-induced diabetes. Curr Neurovasc Res. 2015;12(2):135–146. doi: 10.2174/1567202612666150311111340
   Web of Science ®Google Scholar
• Li G, Regunathan S, Barrow CJ, et al. Agmatine: an endogenous clonidine-displacing substance in the brain. Science. 1994;263(5149):966–969. doi: 10.1126/science.7906055
   PubMed Web of Science ®Google Scholar
• Auguet M, Viossat I, Marin JG, et al. Selective inhibition of inducible nitric oxide synthase by agmatine. Jpn J Pharmacol. 1995;69:285–287. doi: 10.1254/jjp.69.285
   PubMedGoogle Scholar
• Mun CH, Lee WT, Park KA, et al. Regulation of endothelial nitric oxide synthase by agmatine after transient global cerebral ischemia in rat brain. Anat Cell Biol. 2010;43:230–240. doi: 10.5115/acb.2010.43.3.230
   Google Scholar
• Luszczki JJ, Czernecki R, Wojtal K, et al. Agmatine enhances the anticonvulsant action of phenobarbital and valproate in the mouse maximal electroshock seizure model. J Neural Transm. 2008;115(1):1485–1494. doi: 10.1007/s00702-008-0046-3
   Web of Science ®Google Scholar
• Gilad GM, Salame K, Rabey JM, et al. Agmatine treatment is neuroprotective in rodent brain injury models. Life Sci. 1995;58:PL41–PL46. doi: 10.1016/0024-3205(95)02274-0
   Web of Science ®Google Scholar
• Gilad GM, Gilad VH. Accelerated functional recovery and neuroprotection by agmatine after spinal cord ischemia. Neurosci Lett. 2000;296(2–3):97–100. doi: 10.1016/S0304-3940(00)01625-6
   Web of Science ®Google Scholar
• Wang WP, Iyo AH, Miguel-Hidalgo J, et al. Agmatine protects against cell damage induced by NMDA and glutamate in cultured hippocampal neurons. Brain Res. 2006;1084(1):210–216. doi: 10.1016/j.brainres.2006.02.024
   Web of Science ®Google Scholar
• Aricioglu F, Altunbas H. Is agmatine an endogenous anxiolytic/antidepressant agent? Ann N Y Acad Sci. 2003;1009:136–140. doi: 10.1196/annals.1304.014
   Web of Science ®Google Scholar
• Aricioglu F, Regunathan S. Agmatine attenuates stress- and lipopolysaccharide-induced fever in rats. Physiol Behav. 2005;85(3):370–375. doi: 10.1016/j.physbeh.2005.05.004
   Web of Science ®Google Scholar
• Aricioglu-Kartal F, Means A, Regunathan S. Effect of agmatine on the development of morphine dependence in rats: potential role of cAMP system. Eur J Pharmacol. 2004;540:191–197. doi: 10.1016/j.ejphar.2004.10.011
   Web of Science ®Google Scholar
• Regunathan S. Agmatine: biological role and therapeutic potentials in morphine analgesia and dependence. AAPS J. 2006;8:479–484. doi: 10.1208/aapsj080356
   PubMed Web of Science ®Google Scholar
• Aricioglu F, Korcegez E, Bozkurt A, et al. Effect of agmatine on acute and mononeuropathic pain. Ann N Y Acad Sci. 2003;1009:106–115. doi: 10.1196/annals.1304.010
   Web of Science ®Google Scholar
• Santos ARS, Gadotti VM, Oliveira GL, et al. Mechanisms involved in the antinociception caused by agmatine in mice. Neuropharmacol. 2005;48:1021–1034. doi: 10.1016/j.neuropharm.2005.01.012
   Web of Science ®Google Scholar
• Liu P, Jing Y, Collie ND, et al. Memory-related changes in L-citrulline and agmatine in the rat brain. Hippocampus. 2009;19:597–602. doi: 10.1002/hipo.20561
   Web of Science ®Google Scholar
• Leitch B, Shevtsova O, Reusch K, et al. Spatial learning induced increase in agmatine levels at hippocampal CA1 synapses. Synapse. 2011;65:146–153. doi: 10.1002/syn.20828
   Web of Science ®Google Scholar
• Seo S, Liu P, Leitch B. Spatial learning-induced accumulation of agmatine and glutamate at hippocampal CA1 synaptic terminals. Neuroscience. 2011;192:28–36. doi: 10.1016/j.neuroscience.2011.07.007
   PubMed Web of Science ®Google Scholar
• Liu P, Chary S, Devaraj R, et al. Effects of aging on agmatine levels in memory-associated brain structures. Hippocampus. 2008;18:853–856. doi: 10.1002/hipo.20448
   Web of Science ®Google Scholar
• Sirvanci-Yalabik M, Sehirli AO, Utkan T, et al. Agmatine, a metabolite of arginine, improves learning and memory in streptozotocin-induced Alzheimer’s disease model in rats. Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology. 2016;26(4):342–354. doi: 10.5455/bcp.20161121125642
   Web of Science ®Google Scholar
• Utkan T, Gocmez SS, Regunathan S, et al. Agmatine, a metabolite L-arginine, reverses scopolamine-induced learning and memory impairment in rats. Pharmacol Biochem Behav. 2012;102:578–584. doi: 10.1016/j.pbb.2012.07.003
   PubMed Web of Science ®Google Scholar
• Rushaidhi M, Collie ND, Zhang H, et al. Agmatine selectively improves behavioural function in aged Male Sprague-Dawley rats. Neuroscience. 2012;218:206–215. doi: 10.1016/j.neuroscience.2012.05.015
   PubMed Web of Science ®Google Scholar
• Rushaidhi M, Zhang H, Liu P. Effects of prolonged agmatine treatment in aged male Sprague-Dawley rats. Neuroscience. 2013;234:116–124. doi: 10.1016/j.neuroscience.2013.01.004
   PubMed Web of Science ®Google Scholar
• Law A, Gauthier S, Quirion R. Say NO to Alzheimer’s disease: the putative links between nitric oxide and dementia of Alzheimer’s type. Brain Res Brain Res Rev. 2001;35:73–96. doi: 10.1016/S0165-0173(00)00051-5
   PubMed Web of Science ®Google Scholar
• Malinski T. Nitric oxide and nitroxidative stress in Alzheimer’s disease. J Alzheimers Dis. 2007;11:207–218. doi: 10.3233/JAD-2007-11208
   PubMed Web of Science ®Google Scholar
• Sugaya K, Chouinard M, Greene R, et al. Molecular indices of neuronal and glial plasticity in the hippocampal formation in a rodent model of age-induced spatial learning impairment. J Neurosci. 1996;16:3427–3443.
   Web of Science ®Google Scholar
• Law A, Dore S, Blackshaw S, et al. Alteration of expression levels of neuronal nitric oxide synthase and haemoxygenase-2 messenger RNA in the hippocampi and cortices of young adult and aged cognitively unimpaired and impaired Long-Evans rats. Neuroscience. 2000;100:769–775. doi: 10.1016/S0306-4522(00)00316-X
   Web of Science ®Google Scholar
• Law A, O’Donnell J, Gauthier S, et al. Neuronal and inducible nitric oxide synthase expressions and activities in the hippocampi and cortices of young adult, aged cognitively unimpaired, and impaired Long-Evans rats. Neuroscience. 2002;112:267–275. doi: 10.1016/S0306-4522(02)00082-9
   PubMed Web of Science ®Google Scholar
• La Porta CA, Comolli R. Age-dependent modulation of PKC isoforms and NOS activity and expression in rat cortex, striatum, and hippocampus. Exp Gerontol. 1999;34:863–874. doi: 10.1016/S0531-5565(99)00057-1
   Web of Science ®Google Scholar
• Liu P, Smith PF, Appleton I, et al. Nitric oxide synthase and arginase in the rat hippocampus and the entorhinal, perirhinal, postrhinal, and temporal cortices: regional variations and age-related changes. Hippocampus. 2003a;13:859–867. doi: 10.1002/hipo.10138
   Web of Science ®Google Scholar
• Liu P, Smith PF, Appleton I, et al. Regional variations and age-related changes in nitric oxide synthase and arginase in the sub-regions of the hippocampus. Neuroscience. 2003b;119:679–687. doi: 10.1016/S0306-4522(03)00210-0
   PubMed Web of Science ®Google Scholar
• Liu P, Smith PF, Appleton I, et al. Age related changes in nitric oxide synthase and arginase in the rat prefrontal cortex. Neurobiol Aging. 2004a;25:547–552. doi: 10.1016/j.neurobiolaging.2003.07.003
   PubMed Web of Science ®Google Scholar
• Liu P, Smith PF, Appleton I, et al. Potential involvement of NOS and arginase in age-related behavioural impairments. Exp Gerontol. 2004b;39:1207–1222. doi: 10.1016/j.exger.2004.04.008
   PubMed Web of Science ®Google Scholar
• Liu P, Smith PF, Appleton I, et al. Hippocampal nitric oxide synthase and arginase and age associated behavioral deficits. Hippocampus. 2005;15:642–655. doi: 10.1002/hipo.20085
   Web of Science ®Google Scholar
• Feng Y, LeBlanc MH. Effect of agmatine on the time course of brain inflammatory cytokines after injury in rat pups. Ann N Y Acad Sci. 2003;1009:152–156. doi: 10.1196/annals.1304.017
   Web of Science ®Google Scholar
• Molderings GJ, Haenisch B. Agmatine (decarboxylated L-arginine): physiological role and therapeutic potential. Pharmacol Ther. 2012;133:351–365. doi: 10.1016/j.pharmthera.2011.12.005
   PubMed Web of Science ®Google Scholar
• Piletz JE, Aricioglu F, Cheng JT, et al. Agmatine: clinical applications after 100 years in translation. Drug Discov Today. 2013;18(17–18):880–893. doi: 10.1016/j.drudis.2013.05.017
   PubMed Web of Science ®Google Scholar
• Liu P, Jing Y, Zhang H. Age-related changes in arginine and its metabolites in memory-associated brain structures. Neuroscience. 2009;164:611–628. doi: 10.1016/j.neuroscience.2009.08.029
   PubMed Web of Science ®Google Scholar
• Arteni NS, Lavinsky D, Rodrigues AL, et al. Agmatine facilitates memory of an inhibitory avoidance task in adult rats. Neurobiol Learn Mem. 2002;78:465–469. doi: 10.1006/nlme.2002.4076
   Web of Science ®Google Scholar
• Bergin DH, Liu P. Agmatine protects against β-amyloid 25-35-induced memory impairments in the rat. Neuroscience. 2010;169:794–811. doi: 10.1016/j.neuroscience.2010.05.004
   Web of Science ®Google Scholar
• Moosavi M, Khales GY, Abbasi L, et al. Agmatine protects against scopolamine-induced water maze performance impairment and hippocampal ERK and Akt inactivation. Neuropharmacology. 2012;62:2018–2023. doi: 10.1016/j.neuropharm.2011.12.031
   PubMed Web of Science ®Google Scholar
• Jou SB, Liu IM, Cheng JT. Activation of imidazoline receptor by agmatine to lower plasma glucose in streptozotocin-induced diabetic rats. Neurosci Lett. 2004;368:111–111. doi: 10.1016/j.neulet.2004.01.011
   Web of Science ®Google Scholar
• Herrera MD, Mingorance C, Rodriguez-Rodriguez R, et al. Endothelial dysfunction and aging: an update. Ageing Res Rev. 2010;9(2):142–152. doi: 10.1016/j.arr.2009.07.002
   PubMed Web of Science ®Google Scholar
• Förstermann U, Sessa WC. Nitric oxide synthases: regulation and function. Eur Heart J. 2012;33(7):829–837. doi: 10.1093/eurheartj/ehr304
   PubMed Web of Science ®Google Scholar
• Lakatta EG. Arterial and cardiac aging: major share holders in cardiovascular disease enterprises: part I: aging arteries: a “set up” for vascular disease. Circulation. 2003;107(1):139–146. doi: 10.1161/01.CIR.0000048892.83521.58
   PubMed Web of Science ®Google Scholar
• Regunathan S, Piletz JE. Regulation of inducible nitric oxide synthase and agmatine synthesis in macrophages and astrocytes. Ann N Y Acad Sci. 2003;1009:20–29. doi: 10.1196/annals.1304.002
   PubMed Web of Science ®Google Scholar
• Arndt MA, Battaglia V, Parisi E, et al. The arginine metabolite agmatine protects mitochondrial function and confers resistance to cellular apoptosis. Am J Physiol Cell Physiol. 2009;296:C1411–C1419. doi: 10.1152/ajpcell.00529.2008
   PubMed Web of Science ®Google Scholar
• Hong S, Kim CY, Lee JE, et al. Agmatine protects cultured retinal ganglion cells from tumor necrosis factor-alpha induced apoptosis. Life Sci. 2009;84:28–32. doi: 10.1016/j.lfs.2008.10.006
   PubMed Web of Science ®Google Scholar
• Satriano J. Agmatine: at the crossroads of the arginine pathways. Ann N Y Acad Sci. 2003;1009:34–43. doi: 10.1196/annals.1304.004
   PubMed Web of Science ®Google Scholar
• Gong X, Ma Y, Ruan Y, et al. Long-term atorvastatin improves age-related endothelial dysfunction by ameliorating oxidative stress and normalizing eNOS/iNOS imbalance in rat aorta. Exper Ger. 2014;52:9–17. doi: 10.1016/j.exger.2014.01.015
   PubMed Web of Science ®Google Scholar
• Halaris A, Piletz J. Agmatine: metabolic pathway and spectrum of activity in brain. CNS Drugs. 2007;21:885–900. doi: 10.2165/00023210-200721110-00002
   PubMed Web of Science ®Google Scholar
• Regunathan S, Feinstein DL, Reis DJ. Anti-proliferative and antiinflammatory actions of imidazoline agents. Are imidazoline receptors involved? Ann N Y Sci. 1999;881:410–419. doi: 10.1111/j.1749-6632.1999.tb09389.x
   Web of Science ®Google Scholar
• van der Loo B, Labugger R, Skepper JN, et al. Enhanced peroxynitrite formation is associated with vascular aging. J Exp Med. 2000;192:1731–1744. doi: 10.1084/jem.192.12.1731
   PubMed Web of Science ®Google Scholar
• Yamada K, Nabeshima T. Brain-derived neurotrophic factor/TrkB signaling in memory processess. J Pharmacol Sci. 2003;91:267–270. doi: 10.1254/jphs.91.267
   PubMed Web of Science ®Google Scholar